---
schema_version: "secwatch.filing_event.v1"
accession: "0001370053-23-000039"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T03:48:29.917350+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio reports Q1 net loss of $44.3M; initiates Phase 2b for ANB032 in atopic dermatitis

## Summary
- Net loss of $44.3M ($1.58 per share) vs $36.3M loss in Q1 2022; R&D expenses rose to $35.0M.
- Cash and investments totaled $526.1M; reiterated cash runway through year-end 2026.
- Completed $50M stock repurchase program authorized in January 2023.
- Initiated global Phase 2b trial for ANB032 (BTLA agonist) in moderate-to-severe atopic dermatitis; top-line data expected by year-end 2024.
- Plans to start Phase 2b trial for rosnilimab in rheumatoid arthritis in Q3 2023 and second Phase 2 trial by year-end 2023.

## SEC filing metadata
- accession: 0001370053-23-000039
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000137005323000039/0001370053-23-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000137005323000039/anab-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001370053-23-000039
- JSON: https://secwatch.observer/filing/0001370053-23-000039.json
- Plain text: https://secwatch.observer/filing/0001370053-23-000039.txt

## Key facts
- Earnings Releases
  ANAPTYSBIO, INC reported financial results for the three months ended March 31, 2023.
  - Period: the three months ended March 31, 2023
  - Result: reported results
  source text: On May 11, 2023, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1370053/000137005323000039/0001370053-23-000039-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.